New AIDS Drug 'Incredibly Encouraging'
Isentress Works When All Other AIDS Drugs Fail, Study Shows
New AIDS Drug, New HIV Target continued...
The Isentress results are based on only 16 weeks of treatment, although early 24-week results look as good. Eron warns that the durability of the treatment remains unproved.
Yet normally cautious AIDS researchers say it's been a very long time since they've seen such promising findings.
One is Amneris Luque, MD, medical director of the AIDS Center at the University of Rochester, New York.
"This is the road to hope for people who have failed all other AIDS medications," Luque tells WebMD. "It is very impressive to see these kinds of numbers in patients who have developed resistance to other medications."
Another is AIDS treatment pioneer Margaret A. Fischl, MD, director of AIDS research at the University of Miami. Fischl attended the reports by Eron and others.
"I think everyone at the conference was very impressed by this integrase inhibitor," Fischl tells WebMD. "No matter how you looked at it, you saw the integrase inhibitor did very well."
Fischl, too, pointed to the difficulty of treating the kind of patients in the Isentress study.
"You are looking at patients who had been on potent antiviral therapy for a decade -- and they failed that," she says. "So yes, I am impressed."
Carlos del Rio, MD, chief of medicine at Grady Memorial Hospital and professor of medicine at Emory University, Atlanta, treated many of the study patients.
"It is an incredible drug, an amazing drug," del Rio tells WebMD. "With this drug we are able to see some pretty remarkable results."
So far, Isentress seems remarkably safe. It did not seem to cause any adverse events not seen in patients who received a placebo. Fewer than 2% of patients in the trial dropped out due to adverse events.
But all the experts who spoke with WebMD warn that only time will tell. Many other HIV drugs have shown their toxic side only after extended use.
Like all other anti-HIV drugs, the AIDS virus can become resistant to Isentress. Eron warns that doctors must be very careful about how they use the drug.
"The key here is that we need to remember to work as hard as we can to combine even this new, very active drug with other very active drugs," he says.